Evidence map›Paper›PMID 33298905›Full record

ArticleHuman genome variation2020

Rare single-nucleotide DAB1 variants and their contribution to Schizophrenia and autism spectrum disorder susceptibility.

Yoshihiro Nawa, Hiroki Kimura, Daisuke Mori, Hidekazu Kato, Miho Toyama, Sho Furuta, Yanjie Yu, Kanako Ishizuka, Itaru Kushima, Branko Aleksic and 14 more

Open access · goldAbstract read
In one paragraph

Article in Human genome variation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Autism spectrum disorder and schizophrenia: An updated conceptual review.Autism research : official journal of the International Society for Autism Research · 2022
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 1 country.

Yoshihiro NawaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0003-3164-2519
Hiroki KimuraDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. kimura.hiroki@med.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0002-0610-7904
Daisuke MoriDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0002-9072-2546
Hidekazu KatoDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0001-9995-504X
Miho ToyamaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Sho FurutaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Yanjie YuDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Kanako IshizukaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0003-0747-7269
Itaru KushimaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0002-0018-5178
Branko AleksicDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0001-8982-4580
Yuko AriokaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0002-1792-8812
Mako MorikawaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Takashi OkadaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Toshiya InadaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Kozo KaibuchiDepartment of Cell Pharmacology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Masashi IkedaDepartment of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.ORCID http://orcid.org/0000-0001-6237-2449
Nakao IwataDepartment of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.ORCID http://orcid.org/0000-0003-3189-6076
Michio SuzukiDepartment of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
Yuko OkahisaDepartment of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Jun EgawaDepartment of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Toshiyuki SomeyaDepartment of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Fumichika NishimuraOffice for Mental Health Support, Center for Research on Counseling and Support Services, The University of Tokyo, Tokyo, Japan.
Tsukasa SasakiDepartment of Physical and Health Education, Graduate School of Education, The University of Tokyo, Tokyo, Japan.
Norio OzakiDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0002-7360-4898
Nagoya University · JPFujita Health University · JPNagoya University Hospital · JPNiigata University · JPJapan Graduate School of Education University · JPOkayama University · JPTokyo University of Social Welfare · JPUniversity of Toyama · JP

Funding

Japan Agency for Medical Research and Development (AMED) JP18dk0307075Japan Agency for Medical Research and Development (AMED) JP18dk0307081Japan Agency for Medical Research and Development (AMED) JP18dm0107087Japan Agency for Medical Research and Development (AMED) JP18dm0207005
6 · The paper itself

Abstract

Disabled 1 (DAB1) is an intracellular adaptor protein in the Reelin signaling pathway and plays an essential role in correct neuronal migration and layer formation in the developing brain. DAB1 has been repeatedly reported to be associated with neurodevelopmental disorders including schizophrenia (SCZ) and autism spectrum disorders (ASD) in genetic, animal, and postmortem studies. Recently, increasing attention has been given to rare single-nucleotide variants (SNVs) found by deep sequencing of candidate genes. In this study, we performed exon-targeted resequencing of DAB1 in 370 SCZ and 192 ASD patients using next-generation sequencing technology to identify rare SNVs with a minor allele frequency <1%. We detected two rare missense mutations (G382C, V129I) and then performed a genetic association study in a sample comprising 1763 SCZ, 380 ASD, and 2190 healthy control subjects. Although no statistically significant association with the detected mutations was observed for either SCZ or ASD, G382C was found only in the case group, and in silico analyses and in vitro functional assays suggested that G382C alters the function of the DAB1 protein. The rare variants of DAB1 found in the present study should be studied further to elucidate their potential functional relevance to the pathophysiology of SCZ and ASD.

Identifiers

PMID33298905
PMCPMC7655853
OpenAlexW3104716103

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.